Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.
10.1016/j.apsb.2014.05.002
- Author:
Jinhong CHANG
1
;
Fang GUO
1
;
Xuesen ZHAO
1
;
Ju-Tao GUO
1
Author Information
1. Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA 18902, USA.
- Publication Type:Journal Article
- Keywords:
Antiviral agents;
Hepatitis B virus;
cccDNA
- From:
Acta Pharmaceutica Sinica B
2014;4(4):248-257
- CountryChina
- Language:English
-
Abstract:
Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related disease progression and reduction in mortality related to chronic hepatitis B associated liver decompensation and hepatocellular carcinoma. However, chronic HBV infection remains not cured. The reasons for the failure to eradicate HBV infection by long-term antiviral therapy are not completely understood. However, clinical studies suggest that the intrinsic stability of the nuclear form of viral genome, the covalently closed circular (ccc) DNA, sustained low level viral replication under antiviral therapy and homeostatic proliferation of hepatocytes are the critical virological and pathophysiological factors that affect the persistence and therapeutic outcomes of HBV infection. More importantly, despite potent suppression of HBV replication in livers of the treated patients, the dysfunction of HBV-specific antiviral immunity persists. The inability of the immune system to recognize cells harboring HBV infection and to cure or eliminate cells actively producing virus is the biggest challenge to finding a cure. Unraveling the complex virus-host interactions that lead to persistent infection should facilitate the rational design of antivirals and immunotherapeutics to cure chronic HBV infection.
